Octagon Capital Advisors LP Reports 10.1% Passive Stake in AN2 Therapeutics as of June 13 - SEC Filing
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.